Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more
Microba Life Sciences Ltd (MAP) - Net Assets
Latest net assets as of June 2025: AU$32.49 Million AUD
Based on the latest financial reports, Microba Life Sciences Ltd (MAP) has net assets worth AU$32.49 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$47.44 Million) and total liabilities (AU$14.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$32.49 Million |
| % of Total Assets | 68.5% |
| Annual Growth Rate | 17.17% |
| 5-Year Change | 117.55% |
| 10-Year Change | N/A |
| Growth Volatility | 59.32 |
Microba Life Sciences Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Microba Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual net assets of Microba Life Sciences Ltd from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$32.49 Million | -21.16% |
| 2023-12-31 | AU$41.22 Million | +6.43% |
| 2022-12-31 | AU$38.72 Million | +15.47% |
| 2021-12-31 | AU$33.54 Million | +124.53% |
| 2020-12-31 | AU$14.94 Million | +93.88% |
| 2019-12-31 | AU$7.70 Million | -38.64% |
| 2018-12-31 | AU$12.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Microba Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7324589400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$108.54 Million | 334.05% |
| Other Comprehensive Income | AU$2.71 Million | 8.34% |
| Total Equity | AU$32.49 Million | 100.00% |
Microba Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Microba Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OptiCept Technologies AB
ST:OPTI
|
$10.43 Million |
|
Springwater Special Situations Corp
NASDAQ:SWSS
|
$10.43 Million |
|
TBH Global Co Ltd
KO:084870
|
$10.44 Million |
|
Berkem Group SA
PA:ALKEM
|
$10.44 Million |
|
JNB Co., Ltd.
KQ:452160
|
$10.42 Million |
|
Omni-Lite Industries Canada Inc
OTCQX:OLNCF
|
$10.42 Million |
|
Delignit AG
XETRA:DLX
|
$10.42 Million |
|
Umpas Holding AS
IS:UMPAS
|
$10.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Microba Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 41,216,000 to 32,493,487, a change of -8,722,513 (-21.2%).
- Net loss of 14,939,471 reduced equity.
- Share repurchases of 384,660 reduced equity.
- New share issuances of 6,046,002 increased equity.
- Other comprehensive income increased equity by 555,614.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-14.94 Million | -45.98% |
| Share Repurchases | AU$384.66K | -1.18% |
| Share Issuances | AU$6.05 Million | +18.61% |
| Other Comprehensive Income | AU$555.61K | +1.71% |
| Other Changes | AU$2.00 | +0.0% |
| Total Change | AU$- | -21.16% |
Book Value vs Market Value Analysis
This analysis compares Microba Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.85x to 1.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | AU$0.04 | AU$0.08 | x |
| 2019-12-31 | AU$0.03 | AU$0.08 | x |
| 2020-12-31 | AU$0.05 | AU$0.08 | x |
| 2021-12-31 | AU$0.12 | AU$0.08 | x |
| 2022-12-31 | AU$0.12 | AU$0.08 | x |
| 2023-12-31 | AU$0.10 | AU$0.08 | x |
| 2024-12-31 | AU$0.07 | AU$0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Microba Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95.34%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.46x
- Recent ROE (-45.98%) is above the historical average (-47.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -37.70% | -258.94% | 0.13x | 1.11x | AU$-5.99 Million |
| 2019 | -86.33% | -228.62% | 0.27x | 1.40x | AU$-7.42 Million |
| 2020 | -50.37% | -201.58% | 0.20x | 1.24x | AU$-9.02 Million |
| 2021 | -34.20% | -244.64% | 0.12x | 1.18x | AU$-14.82 Million |
| 2022 | -32.87% | -233.95% | 0.12x | 1.22x | AU$-16.54 Million |
| 2023 | -48.38% | -164.92% | 0.21x | 1.41x | AU$-24.06 Million |
| 2024 | -45.98% | -95.34% | 0.33x | 1.46x | AU$-18.19 Million |
Industry Comparison
This section compares Microba Life Sciences Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $173,640,009
- Average return on equity (ROE) among peers: -26.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Microba Life Sciences Ltd (MAP) | AU$32.49 Million | -37.70% | 0.46x | $10.42 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $217.50 Million |
| Bcal Diagnostics Ltd (BDX) | $6.22 Million | -116.40% | 0.59x | $10.33 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $5.03 Million |
| Genetic Signatures Ltd (GSS) | $16.18 Million | -10.68% | 0.02x | $8.20 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $208.81 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $23.33 Million |
| Monash Ivf Group Ltd (MVF) | $268.44 Million | 9.37% | 0.33x | $116.82 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $89.67 Million |